Chimeric antigen receptor T-cell therapy, more commonly known as CAR-T therapy, has been hailed as a potentially game-changing cancer treatment with extraordinary promise. Representing a new frontier in immuno-oncology and gene therapy, CAR-T therapy has demonstrated rapid and complete responses in highly refractory patients in clinical trials. Emerging data has clearly shown CAR-T’s significant potential for improved outcomes in relapsed/refractory DLBCL, primary mediastinal B-cell lymphoma, chronic lympocytic leukemia and acute lympoblastic leukemia.
With the recent FDA approval of two new treatments, CAR-T is now making its way to market. In spite of its significant potential, the degree to which oncologists will refer patients for CAR-T therapy is still unknown. CAR-T manufacturers have indicated to the FDA that treatments will be initially limited to highly-specialized centers capable of stem cell transplantation. However, with the majority of cancer patients being seen in the community setting, the perception of this treatment among community oncologists will be vital to its success, patient referrals, and initial adoption.
Cardinal Health Specialty Solutions conducted research to better understand the challenges that may hinder community oncologists’ use and referral of CAR-T therapy. The findings were published in the October 2017 issue of Journal of Clinical Pathways.